These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 24491043)

  • 1. Role of CDH1 promoter polymorphism and DNA methylation in bladder carcinogenesis: a meta-analysis.
    Wang Y; Kong CZ; Zhang Z; Yang CM; Li J
    DNA Cell Biol; 2014 Apr; 33(4):205-16. PubMed ID: 24491043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of CDH1 promoter methylation in colorectal carcinogenesis: a meta-analysis.
    Li YX; Lu Y; Li CY; Yuan P; Lin SS
    DNA Cell Biol; 2014 Jul; 33(7):455-62. PubMed ID: 24684676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. E-cadherin gene promoter hypermethylation may contribute to the risk of bladder cancer among Asian populations.
    Li G; Liu Y; Yin H; Zhang X; Mo X; Tang J; Chen W
    Gene; 2014 Jan; 534(1):48-53. PubMed ID: 24404589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Promoter methylation and polymorphism of E-cadherin gene may confer a risk to prostate cancer: a meta-analysis based on 22 studies.
    Chang Z; Zhou H; Liu Y
    Tumour Biol; 2014 Oct; 35(10):10503-13. PubMed ID: 25056535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of genetic variants in and promoter hypermethylation of CDH1 with gastric cancer: a meta-analysis.
    Jing H; Dai F; Zhao C; Yang J; Li L; Kota P; Mao L; Xiang K; Zheng C; Yang J
    Medicine (Baltimore); 2014 Oct; 93(19):e107. PubMed ID: 25340495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The association between CDH1 promoter methylation and patients with ovarian cancer: a systematic meta-analysis.
    Wang Q; Wang B; Zhang YM; Wang W
    J Ovarian Res; 2016 Apr; 9():23. PubMed ID: 27067410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological significance and potential drug targeting of CDH1 in lung cancer: a meta-analysis and literature review.
    Yu Q; Guo Q; Chen L; Liu S
    Drug Des Devel Ther; 2015; 9():2171-8. PubMed ID: 25931811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypermethylation of an E-cadherin (CDH1) promoter region in high grade transitional cell carcinoma of the bladder comprising carcinoma in situ.
    Horikawa Y; Sugano K; Shigyo M; Yamamoto H; Nakazono M; Fujimoto H; Kanai Y; Hirohashi S; Kakizoe T; Habuchi T; Kato T
    J Urol; 2003 Apr; 169(4):1541-5. PubMed ID: 12629411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of RASSF1A promoter methylation in the pathogenesis of ovarian cancer: a meta-analysis.
    Si JG; Su YY; Han YH; Chen RH
    Genet Test Mol Biomarkers; 2014 Jun; 18(6):394-402. PubMed ID: 24665911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationships between p16 gene promoter methylation and clinicopathologic features of colorectal cancer: a meta-analysis of 27 cohort studies.
    Chen YZ; Liu D; Zhao YX; Wang HT; Gao Y; Chen Y
    DNA Cell Biol; 2014 Oct; 33(10):729-38. PubMed ID: 24979649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA polymorphisms in exon 1 and promoter of the CDH1 gene and relevant risk of transitional cell carcinoma of the urinary bladder.
    Ma X; Xu H; Zheng T; Li HZ; Shi TP; Wang BJ; Ju ZH; Wang C; Zhang GX; Zhang X
    BJU Int; 2008 Aug; 102(5):633-6. PubMed ID: 18384629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathological significance and potential drug target of CDH1 in breast cancer: a meta-analysis and literature review.
    Huang R; Ding P; Yang F
    Drug Des Devel Ther; 2015; 9():5277-85. PubMed ID: 26425077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CDH1 polymorphisms and haplotypes in sporadic diffuse and intestinal gastric cancer: a case-control study based on direct sequencing analysis.
    Chu CM; Chen CJ; Chan DC; Wu HS; Liu YC; Shen CY; Chang TM; Yu JC; Harn HJ; Yu CP; Yang MH
    World J Surg Oncol; 2014 Mar; 12():80. PubMed ID: 24684952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of CDH13 promoter methylation as a biomarker for bladder cancer: a meta-analysis.
    Chen F; Huang T; Ren Y; Wei J; Lou Z; Wang X; Fan X; Chen Y; Weng G; Yao X
    BMC Urol; 2016 Aug; 16(1):52. PubMed ID: 27578166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancer.
    Lin YL; Wang YL; Ma JG; Li WP
    J Exp Clin Cancer Res; 2014 Aug; 33(1):68. PubMed ID: 25927589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. E-cadherin (CDH1) gene -160C/A polymorphism and the risk of colorectal cancer: A meta-analysis involving 17,291 subjects.
    Ye CC; Wang J
    J Gene Med; 2021 Oct; 23(10):e3370. PubMed ID: 34097324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of association between the CDH1 polymorphism and gastric cancer susceptibility: a meta-analysis.
    Jiang B; Zhu K; Shao H; Bao C; Ou J; Sun W
    Sci Rep; 2015 Jan; 5():7891. PubMed ID: 25599647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between the Epithelial Cadherin - 160C/A Polymorphism and Colorectal Cancer Risk: Evidence from a Meta-Analysis.
    Sun N; Chen J; Hu G; Chen X; Jiang J; Zhang L; Wu H
    Crit Rev Eukaryot Gene Expr; 2017; 27(4):347-354. PubMed ID: 29283329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The CDH1 -160C/A polymorphism is associated with breast cancer: evidence from a meta-analysis.
    Ma YY; Wu WQ; Liu ZC; Yu XF; Guo K; He QW; Jiang SB; Shao QS; Tao HQ; Huang DS
    World J Surg Oncol; 2016 Jun; 14(1):169. PubMed ID: 27349965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Associations of RASSF1A, RARβ, and CDH1 promoter hypermethylation with oral cancer risk: A PRISMA-compliant meta-analysis.
    Wen G; Wang H; Zhong Z
    Medicine (Baltimore); 2018 Mar; 97(11):e9971. PubMed ID: 29538221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.